Tetralogic Pharmaceuticals Corporation

Venatorx Pharmaceuticals, Inc.

Tetralogic Birinapant UK Ltd.

Medivir Ab

Aventis Pharmaceuticals Inc.

Wyeth

Viropharma Incorporated

Stephen M. Condon

Susan R. Rippin

Yijun Deng

Matthew G. Laporte

Stephen M Condon

Matthew G Laporte

Susan R Rippin

Christopher J Burns

Steven Armen Boyd

Glen Coburn

Guo-Hua Chu

Jiangchao Yao

Bin Liu

Christopher Benetatos

Jodie Hamrick

Thomas Haimowitz

Daniel C Pevear

Allison L Zulli

Denis Daigle

Robert E Lee Trout

Eugen F Mesaros

Matthew D Alexander

Cullen L Myers

William R Ewing

Alfred P Spada

Timothy Francis Gallagher

Wei He

Heinz W Pauls

Zhenrong Xu

Michael R Myers

Ariamala Gopalsamy

John W Ellingboe

Tarek Suhayl Mansour

Kent W Neuenschwander

Joseph M Karpinski

Robert D Groneberg

Robert L Morris

Yong Mi Choi-Sledeski

Aiwen Li

Gregory Bernard Poli

Barbara Hanney

Jean-Francois Sabuco

Michael R Becker

Mark A Bobko

John Ziqi Jiang

Kaapjoo Park

Roderick S Davis

Matthew Lucas

Susan R Rippen

Isabelle Morize

Marc S Collett

Wan F Lau

Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

Penicillin-binding protein inhibitors

Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

Orally-bioavailable nucleoside analogs

The present disclosure provides broad-spectrum carbapenem derivatives and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such derivatives and/or compositions.

Broad-spectrum carbapenems

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

SMAC mimetic

Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

Hepatitis B capsid assembly modulators

SMAC Mimetic

Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.

Dimeric IAP inhibitors

Growing community of inventors

Glenmoore, PA, United States of America

Stephen M Condon